Acadia Pharmaceuticals | ACAD - Cost Of Sales

Stock Price
23.53
Daily Change
0.07 0.30%
Monthly
-14.19%
Yearly
26.85%
Q1 Forecast
24.36

Acadia Pharmaceuticals reported $21.65M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
ALKERMES USD 51.59M 2.13M Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Corcept Therapeutics USD 4.6M 1.16M Sep/2025
Cytokinetics USD 112.55M 12.71M Jun/2025
Eisai JPY 45.52B 2.92B Sep/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Incyte USD 99M 20.23M Sep/2025
J&J USD 7.97B 689M Dec/2025
Moderna USD 207M 88M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Prothena USD 28.94M 11.58M Sep/2025
PTC Therapeutics USD 23.32M 7.83M Sep/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025